27 results
8-K
EX-99.1
GMDAQ
Gamida Cell Ltd
10 May 22
Gamida Cell Reports First Quarter 2022 Financial Results
7:30am
(73% vs 60%).
A health economic study titled “Projected Impact of Omidubicel on Racial and Ethnic Disparities in Allogeneic Hematopoietic Cell … of omidubicel on racial and ethnic health disparities in a projection model, showed that, if approved, broad access to omidubicel was projected to decrease time
8-K
EX-99.1
GMDAQ
Gamida Cell Ltd
14 Nov 22
Gamida Cell Reports Third Quarter 2022 Financial Results
7:15am
and ethnic minorities by extending access and reducing time to transplant for patients who may not be able to currently find a donor source.
Appointed … , with the greatest improvements among the racial and ethnic groups underserved by the current standard of care. In a third poster, results of a translational
6-K
EX-99.1
GMDAQ
Gamida Cell Ltd
10 Feb 21
Current report (foreign)
4:01pm
Efficacy and Safety Results Shared at the TCT Meetings
Patient demographics including racial and ethnic diversity and baseline characteristics were well
8-K
EX-99.1
GMDAQ
Gamida Cell Ltd
27 Sep 23
Regulation FD Disclosure
4:43pm
Cell market research.
Be The Match® website (accessed 5/30/23); IT-Ideation Department, February 2021 (ethnic background %).
Contraindications
8-K
EX-99.1
GMDAQ
Gamida Cell Ltd
27 Mar 24
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update
7:30am
of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies
8-K
EX-99.1
vxfhu2dm
17 Apr 23
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
5:29pm
6-K
EX-99.1
ie5p0iql7y c0p
11 May 21
Gamida Cell Reports First Quarter 2021 Financial Results and Provides Company Update
8:28am
424B5
9to5zd0061c3181ltm8h
27 Sep 22
Prospectus supplement for primary offering
5:01pm
424B5
w7lr79ad0
29 Sep 22
Prospectus supplement for primary offering
4:08pm
10-K
qn3mdd
24 Mar 22
Annual report
7:30am
10-Q
3qytzgfr80fzyo
12 May 22
Quarterly report
7:42am
20-F
21ssrm
25 Feb 19
Annual report (foreign)
5:08pm
F-1
vymda 5qz
28 Sep 18
Registration statement (foreign)
4:29pm
424B4
dsxygih6hzhs6x
28 Jun 19
Prospectus supplement with pricing info
3:51pm